Advertisement
Screener

NEXTCURE, INC (NXTC) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

NextCure, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • NextCure, Inc. return tang equity for the quarter ending 2026-06-30 was -351.86%, a change of -146.35% year-over-year.
  • NextCure, Inc. return tang equity for the quarter ending 2026-03-31 was -204.61%, a change of -115.95% year-over-year.
  • NextCure, Inc. return tang equity for the quarter ending 2025-12-31 was -159.81%, a change of -74.81% year-over-year.
  • NextCure, Inc. return tang equity for the quarter ending 2025-09-30 was -245.33%, a change of -167.92% year-over-year.
  • NextCure, Inc. return tang equity for fiscal 2025 was -159.81%, a change of -74.81% from fiscal 2024.
  • NextCure, Inc. return tang equity for fiscal 2024 was -85.00%, a change of -30.19% from fiscal 2023.
  • NextCure, Inc. return tang equity for fiscal 2023 was -54.82%, a change of -10.21% from fiscal 2022.
  • NextCure, Inc. return tang equity for fiscal 2022 was -44.61%, a change of -14.88% from fiscal 2021.
Available history
2018-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-351.86%-$42.75M$12.15M
2026-03-31-204.61%-$54.66M$26.72M
2025-12-31-159.81%-$55.84M$34.94M
2025-09-30-245.33%-$58.01M$23.65M
2025-06-30-205.52%-$60.93M$29.65M
2025-03-31-88.66%-$49.52M$55.86M
2024-12-31-85.00%-$55.65M$65.47M
2024-09-30-77.41%-$58.52M$75.59M
2024-06-30-71.72%-$61.28M$85.44M
2024-03-31-64.35%-$63.73M$99.05M
2023-12-31-54.82%-$62.72M$114.42M
2023-09-30-51.84%-$65.56M$126.45M
2023-06-30-50.69%-$70.17M$138.43M
2023-03-31-45.54%-$70.23M$154.2M
2022-12-31-44.61%-$74.73M$167.53M
2022-09-30-40.97%-$74.37M$181.54M
2022-06-30-37.03%-$73.39M$198.2M
2022-03-31-34.34%-$73.46M$213.94M
2021-12-31-29.73%-$69.39M$233.39M
2021-09-30-27.36%-$67.91M$248.23M
2021-06-30-25.17%-$66.35M$263.6M
2021-03-31-22.52%-$62.87M$279.16M
2020-12-31-12.46%-$36.6M$293.72M
2020-09-30-10.43%-$32.07M$307.34M
2020-06-30-7.50%-$24.14M$321.92M
2020-03-31-5.38%-$17.85M$331.76M
2019-12-31-10.49%-$33.74M$321.48M
2019-09-30-17.39%-$29.67M$170.65M
2019-06-30-15.09%-$26.95M$178.6M
2019-03-3145.45%-$23.96M-$52.71M
2018-12-3148.57%-$22.8M-$46.94M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-159.81%-$55.84M$34.94M
2024-12-31-85.00%-$55.65M$65.47M
2023-12-31-54.82%-$62.72M$114.42M
2022-12-31-44.61%-$74.73M$167.53M
2021-12-31-29.73%-$69.39M$233.39M
2020-12-31-12.46%-$36.6M$293.72M
2019-12-31-10.49%-$33.74M$321.48M
2018-12-3148.57%-$22.8M-$46.94M

Similar stocks

Stock NameCountryMarket CapPE Ratio
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Cocrystal Pharma, Inc. (COCP)United States$0.022B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86